| Literature DB >> 28087387 |
Fen Tang1, Xiaoqing Chen1, Yuxiang Mao1, Shangtao Wan1, Siming Ai1, Huasheng Yang1, Guangming Liu1, Yusha Zou1, Miaoli Lin2, Liang Dan3.
Abstract
The success of rituximab for the treatment of active Graves' orbitopathy (GO) suggests that B cells play a critical role in intraorbital inflammation. B cell activating factor (BAFF) and its homolog a proliferation-inducing ligand (APRIL) are critical for B cell survival. However, the contribution of BAFF/APRIL to GO remains unclear. We sought to determine the role of BAFF/APRIL in the orbits of GO, and found that BAFF was markedly upregulated, while APRIL was not. Additionally, cultured GO orbital fibroblasts (GO-OFs)2 expressing BAFF were induced to produce a large amount of BAFF. In contrast, a weak APRIL expression was detected in the OFs, and they exhibited a slight response to stimulation. Notably, pretreated GO-OFs promoted B cell survival, and this effect was significantly inhibited by a BAFF-R neutralizing antibody. This study indicates that OFs from GO can express BAFF and mediate the intraorbital survival of B cells via BAFF mechanism.Entities:
Keywords: A proliferation-inducing ligand (APRIL); B-cell activating factor (BAFF); Graves' orbitopathy; Orbital fibroblasts
Mesh:
Substances:
Year: 2017 PMID: 28087387 DOI: 10.1016/j.mce.2017.01.014
Source DB: PubMed Journal: Mol Cell Endocrinol ISSN: 0303-7207 Impact factor: 4.102